Entera Bio Ltd. Capex per Share

Capex per Share of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capex per Share growth rates and interactive chart. Capex per share refers to the total amount of capital expenditures paid in a period divided by the weighted average number of shares outstanding. If a company has capex of $100 million and 10 million shares outstanding, capex per share is $10.


Highlights and Quick Summary

  • Capex per Share for the quarter ending June 29, 2020 was 0.0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Capex per Share decreased by -100.0%
  • Annual Capex per Share for 2019 was -0.0 (a -61.18% decrease from previous year)
  • Annual Capex per Share for 2018 was -0.01 (a -25.44% decrease from previous year)
  • Twelve month Capex per Share ending June 29, 2020 was -0.0 (a -10.0% decrease compared to previous quarter)
  • Twelve month trailing Capex per Share decreased by -45.45% year-over-year
Trailing Capex per Share for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-0.0 -0.0 -0.0 -0.0
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capex per Share of Entera Bio Ltd.

Most recent Capex per Shareof ENTX including historical data for past 10 years.

Interactive Chart of Capex per Share of Entera Bio Ltd.

Entera Bio Ltd. Capex per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0 -0.0
2019 0.0 0.0 -0.0 -0.0 -0.0
2018 0.0 0.0 -0.0 -0.01 -0.01
2017 0.0 -0.01

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.